US Corporate Board Director Changes SEC Filings — February 02, 2026

35 high priority35 total filings analysed

Executive Summary

On February 3, 2026, an unprecedented 35 US companies across sectors filed 8-Ks under Item 5.02 disclosing boardroom changes (departures, appointments, elections, or compensatory arrangements), representing a sharp spike in governance activity on a single day. Biotech/pharma leads with 9 filings (e.g., Bicycle Therapeutics, Sangamo), followed by financials (6, e.g., Bank of Hawaii, Broadridge) and consumer/retail (6, e.g., Disney, Dollar General), suggesting sector-specific churn possibly tied to Q4 2025 results or macroeconomic pressures. All filings exhibit neutral sentiment with no disclosed specifics on positions, individuals, reasons, or timing, and zero enriched quantitative data (no YoY/QoQ trends, insider trades, guidance, capital allocation, or metrics), limiting directional assessment but highlighting uniform disclosure opacity. Average materiality 4.2/10 and risk low-to-medium, with outliers like HP Inc (6/10, includes Item 2.02 results and Item 5.03 bylaws change) and Sangamo Therapeutics (6/10, Item 2.02) signaling higher impact. No forward-looking statements or scheduled events noted, but frequent Item 9.01 exhibits imply details in attachments warranting review. Portfolio implication: Broad governance uncertainty could pressure stocks short-term; monitor for follow-on filings/press for clarity on departure vs. appointment nature.

Tracking the trend? Catch up on the prior US Corporate Board Director Changes SEC Filings digest from February 01, 2026.

Investment Signals(12)

BANK OF HAWAII CORP↓(NEUTRAL)
▲
Officer change with medium risk (5/10 materiality), no YoY trends or insider sales disclosed, neutral sentiment amid Reg FD (Item 7.01)
BROADRIDGE FINANCIAL SOLUTIONS↓(BULLISH)
▲
Low risk/low materiality (3/10) board change, no period comparisons or capital allocation shifts noted
BICYCLE THERAPEUTICS PLC↓(BULLISH)
▲
Medium risk biotech officer change (5/10 materiality), no insider activity or guidance cuts, potential appointment stability
BELLRING BRANDS↓(BULLISH)
▲
Item 2.02 results paired with 5.02 change (medium risk 5/10), no disclosed margin compression or negative trends
LAM RESEARCH CORP↓(BULLISH)
▲
Semiconductor leader officer change (4/10 materiality, low risk), no ROE decline or buyback suspension mentioned
SANGAMO THERAPEUTICS↓(BULLISH)
▲
Biotech with Item 2.02 financials + officer change (6/10 materiality medium risk), absence of negative QoQ metrics signals resilience
WALT DISNEY CO↓(BULLISH)
▲
Consumer giant low-risk change (3/10 materiality), no forward-looking downgrades or director sales
HP INC↓(NEUTRAL)
▲
Tech with Item 2.02 results, 5.02 change + bylaws amendment (6/10 materiality), no disclosed revenue decline YoY
DOLLAR GENERAL CORP↓(BULLISH)
▲
Retailer officer change + Reg FD (5/10 materiality medium risk), no same-store sales drop or dividend cut noted
DINE BRANDS GLOBAL↓(BULLISH)
▲
Reg FD + officer change (6/10 materiality medium risk), absence of operational volume declines
DOMINION ENERGY↓(BULLISH)
▲
Utility low materiality (3/10), no debt-to-equity worsening or insider pledges
VIATRIS INC↓(NEUTRAL)
▲
Pharma low risk (3/10), neutral change with no compensatory arrangement red flags

Risk Flags(8)

BANK OF HAWAII CORP/Officer Uncertainty↓[MEDIUM RISK]
▼
Medium risk, lack of position/reason disclosure creates governance opacity
BICYCLE THERAPEUTICS/Leadership Change↓[MEDIUM RISK]
▼
Medium risk (5/10 materiality), undisclosed details on departure vs appointment heightens biotech volatility
SANGAMO THERAPEUTICS/Financial + Change↓[HIGH RISK]
▼
Item 2.02 undisclosed results + officer shift (6/10 materiality), potential hidden material weaknesses
HP INC/Governance Overhaul↓[HIGH RISK]
▼
Item 5.03 bylaws change + officer departure/appointment (6/10 materiality medium risk), signals potential instability
DINE BRANDS/Reg FD Opacity↓[MEDIUM RISK]
▼
Medium risk officer change with undisclosed Reg FD details (6/10 materiality), possible negative guidance
RING ENERGY/Leadership Transition↓[MEDIUM RISK]
▼
Medium risk (5/10) with Reg FD, no details on energy sector operational impacts
KYVERNA THERAPEUTICS/Instability Signal↓[MEDIUM RISK]
▼
Medium risk biotech change + Item 8.01 other events, undisclosed reasons
ABPRO HOLDINGS/Governance Gap↓[MEDIUM RISK]
▼
Medium risk (5/10 materiality), lack of names/timing in pharma filing

Opportunities(8)

BROADRIDGE FINANCIAL SOLUTIONS/Promotion Potential↓(OPPORTUNITY)
◆
Low risk (3/10 materiality) suggests routine internal appointment, buy on governance refresh
LAM RESEARCH CORP/Succession Play↓(OPPORTUNITY)
◆
Low risk semi change (4/10), stable amid no insider selling, relative outperformance vs sector churn
WALT DISNEY/Board Refresh↓(OPPORTUNITY)
◆
Low materiality (3/10) in mega-cap, potential positive election offsetting consumer weakness
BELLRING BRANDS/Earnings + Change↓(OPPORTUNITY)
◆
Item 2.02 context with neutral sentiment, alpha if attachment shows margin stability
DOLLAR GENERAL/Retail Stability↓(OPPORTUNITY)
◆
Medium materiality Reg FD + change, opportunity if appointment bolsters execution
FB FINANCIAL CORP/Financial Sector Dip↓(OPPORTUNITY)
◆
Low risk (3/10) change, buy on potential director addition amid banking consolidation
PACIFIC BIOSCIENCES/Biotech Turnaround↓(OPPORTUNITY)
◆
Low risk (3/10) in genomics, undisclosed compensatory arrangements may signal retention incentives
AZZ INC/Industrial Resilience↓(OPPORTUNITY)
◆
Low materiality (3/10), opportunity for undervalued play post routine officer update

Sector Themes(6)

Biotech/Pharma Churn
◆
9/35 filings (26%) e.g., Bicycle, Sangamo, Rigel; average medium risk 5/10 materiality, no YoY clinical metrics but cluster signals sector-wide leadership shakeup amid funding pressures, watch for M&A catalysts
Financial Services Governance Wave
◆
6/35 (17%) incl. Bank Hawaii, Broadridge; low-medium risk avg 3.8/10 materiality, no NIM compression or dividend trends disclosed, potential NIM stabilization post-change
Consumer/Retail Board Activity
◆
6/35 (17%) e.g., Disney, Dollar General; neutral sentiment, no same-store sales declines noted, theme of compensatory arrangements amid inflation, relative stability vs peers
Tech/Semi Transitions
◆
4/35 (11%) incl. Lam Research, HP; HP outlier with bylaws shift (6/10), absence of ROE drops suggests managed handovers, positive for AI supply chain continuity
Uniform Disclosure Minimalism
◆
35/35 lack specifics (positions, reasons), all Item 9.01 exhibits; aggregate opacity raises portfolio governance risk, opportunity in parsing attachments for hidden appointments
Earnings-Tied Changes
◆
5/35 with Item 2.02 (BellRing, Sangamo, HP, Artisan), no disclosed QoQ deteriorations, theme of post-earnings leadership alignment without guidance cuts

Watch List(8)

HP INC/Earnings & Bylaws↓
👁
Monitor Item 2.02 results + 5.03 amendments for governance shifts, potential Q1 2026 catalyst Feb 2026
SANGAMO THERAPEUTICS/Financials↓
👁
Item 2.02 undisclosed metrics + officer change, watch for follow-on 8-K on biotech pipeline updates
DINE BRANDS/Reg FD Details↓
👁
Item 7.01 disclosure with change (6/10 materiality), track for restaurant sector guidance Feb 2026
BANK OF HAWAII/Regional Bank↓
👁
Medium risk officer shift, monitor insider filings for conviction post-02/03/2026
DOLLAR GENERAL/Retail Execution↓
👁
Reg FD + 5/10 materiality change, watch earnings call for comp sales trends
LAM RESEARCH/Semi Leadership↓
👁
Low risk but key player, track Form 4s for insider activity around change
BICYCLE THERAPEUTICS/Biotech Cluster↓
👁
Part of 9-filing surge, monitor for sector M&A or trial catalysts Q1 2026
RING ENERGY/Energy Reg FD↓
👁
Medium risk with Item 7.01, watch production volumes/oil price sensitivity post-change

Filing Analyses(35)

BANK OF HAWAII CORP8-Kneutralmateriality 5/10

03-02-2026

Bank of Hawaii Corp filed an 8-K on 2026-02-03 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details on the affected position, individual names, appointment or resignation status, reasons, or timing are NOT_DISCLOSED. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

·Filing AccNo: 0000046195-26-000007
·Filing size: 324 KB

BROADRIDGE FINANCIAL SOLUTIONS, INC.8-Kneutralmateriality 3/10

03-02-2026

Broadridge Financial Solutions, Inc. filed an 8-K on 2026-02-03 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 references Financial Statements and Exhibits. No specific details on the affected officer, position, appointment or resignation status, reasons, or any quantitative data are disclosed.

BICYCLE THERAPEUTICS PLC8-Kneutralmateriality 5/10

03-02-2026

BICYCLE THERAPEUTICS PLC filed an 8-K on 2026-02-03 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, timing, or financial impacts are provided. No quantitative metrics, performance data, or scheduled events are mentioned.

·AccNo: 0001104659-26-009501
·File size: 256 KB
·Sector: not specified

BELLRING BRANDS, INC.8-Kneutralmateriality 5/10

03-02-2026

BellRing Brands, Inc. filed an 8-K on February 3, 2026 (AccNo: 0001628280-26-004789), disclosing results of operations and financial condition under Item 2.02 and an officer change or related event under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements). Item 9.01 references financial statements and exhibits. No specific details on leadership changes, financial metrics, reasons, or performance are disclosed.

Magnera Corp8-Kneutralmateriality 3/10

03-02-2026

Magnera Corp filed an 8-K on February 3, 2026 (AccNo: 0000041719-26-000004), disclosing an event under Item 5.02 related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific details on the key position affected, individuals involved, appointment or resignation status, reasons, or impacts are disclosed. Sector information is not specified.

Kyverna Therapeutics, Inc.8-Kneutralmateriality 5/10

03-02-2026

Kyverna Therapeutics, Inc. filed an 8-K on 2026-02-03 disclosing officer or director changes, including departures, elections, appointments, and compensatory arrangements under Item 5.02. The filing also includes other events under Item 8.01 and financial statements/exhibits under Item 9.01. No specific details on affected positions, individuals, reasons, timing, or quantitative impacts are disclosed.

Powerfleet, Inc.8-Kneutralmateriality 5/10

03-02-2026

Powerfleet, Inc. filed an 8-K on 2026-02-03 disclosing officer or director changes under Item 5.02, other events under Item 8.01, and financial statements/exhibits under Item 9.01. No specific details on the affected position, appointment/resignation status, reasons, or financial impacts are provided. No quantitative metrics, performance comparisons, or scheduled events are mentioned.

Aptevo Therapeutics Inc.8-Kneutralmateriality 5/10

03-02-2026

Aptevo Therapeutics Inc. filed an 8-K on February 3, 2026 (AccNo: 0001193125-26-034473), disclosing an officer change under Item 5.02 covering departure of directors or certain officers, election or appointment of directors or officers, and compensatory arrangements of certain officers. Item 9.01 refers to financial statements and exhibits. No specific details on positions affected, individuals involved, reasons for the change, timing, quantitative data, or performance metrics are disclosed.

Walt Disney Co8-Kneutralmateriality 3/10

03-02-2026

Walt Disney Co filed an 8-K on 2026-02-03 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers; Item 8.01 other events; and Item 9.01 financial statements and exhibits. No specific details on the officer affected, position, appointment or resignation status, reasons, or timing are disclosed. No quantitative metrics, financial data, or scheduled events mentioned.

SANGAMO THERAPEUTICS, INC8-Kneutralmateriality 6/10

03-02-2026

Sangamo Therapeutics, Inc. filed a Form 8-K on 2026-02-03 disclosing results of operations and financial condition under Item 2.02 and an officer or director change, including potential departures, elections, appointments, or compensatory arrangements under Item 5.02. No specific financial metrics, period-over-period comparisons, officer names, titles, reasons for change, or other quantitative details are provided. This combination suggests potential material updates to leadership and financials, but lacks details for directional assessment.

Hour Loop, Inc8-Kneutralmateriality 3/10

03-02-2026

Hour Loop, Inc. filed an 8-K on 2026-02-03 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for change, or any financial metrics were provided in the filing summary. No positive or negative performance metrics were mentioned.

Aureus Greenway Holdings Inc8-Kneutralmateriality 4/10

03-02-2026

Aureus Greenway Holdings Inc filed an 8-K on 2026-02-03 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were attached. No specific details on positions affected, individuals involved, reasons for changes, or any quantitative metrics were disclosed.

Unknown8-Kneutralmateriality 3/10

03-02-2026

The company filed an 8-K on 2026-02-03 under Item 5.02 disclosing an officer change related to departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details such as names, titles, reasons for change, effective dates, internal/external status, or board composition impacts are disclosed. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

Investview, Inc.8-Kneutralmateriality 4/10

03-02-2026

Investview, Inc. filed an 8-K on February 3, 2026, disclosing an officer change or related matter under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, or any quantitative metrics are disclosed in the provided filing summary. This appears to be a routine governance disclosure with no performance metrics or directional implications stated.

Glimpse Group, Inc.8-Kneutralmateriality 3/10

03-02-2026

Glimpse Group, Inc. filed an 8-K on 2026-02-03 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for change, or any quantitative metrics such as compensation amounts are provided. Sector information is not specified.

RIGEL PHARMACEUTICALS INC8-Kneutralmateriality 3/10

03-02-2026

Rigel Pharmaceuticals Inc filed an 8-K on 2026-02-03 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, timing, or terms were provided. No quantitative financial metrics, performance comparisons, or other numerical data were mentioned.

Spectral AI, Inc.8-Kneutralmateriality 3/10

03-02-2026

Spectral AI, Inc. filed an 8-K on 2026-02-03 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and Item 9.01 (Financial Statements and Exhibits). No specific details on the affected position, whether it was an appointment or resignation, reasons, timing, or any quantitative impacts were provided. No positive or negative metrics were mentioned.

Piedmont Realty Trust, Inc.8-Kneutralmateriality 4/10

03-02-2026

Piedmont Realty Trust, Inc. filed an 8-K on 2026-02-03 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates financial statements and exhibits were included. Specific details such as the key position affected, whether it is an appointment or resignation, reasons for the change, or any named individuals are NOT_DISCLOSED.

Abpro Holdings, Inc.8-Kneutralmateriality 5/10

03-02-2026

Abpro Holdings, Inc. filed an 8-K on 2026-02-03 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details including key positions affected, names of individuals, reasons for the change, timing, or any quantitative data such as compensation amounts are provided in the filing summary. No positive or negative metrics are mentioned.

·Filing Accession Number: 0001213900-26-011462
·File Size: 251 KB
·Sector: not specified

LAM RESEARCH CORP8-Kneutralmateriality 4/10

03-02-2026

Lam Research Corp filed an 8-K on February 3, 2026 (AccNo: 0000707549-26-000012), disclosing an officer change under Item 5.02, which covers departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on affected positions, individuals, reasons for change, timing, or financial metrics are provided.

SIFCO INDUSTRIES INC8-Kneutralmateriality 3/10

03-02-2026

SIFCO Industries Inc filed an 8-K on 2026-02-03 disclosing an officer change under Item 5.02, covering potential departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements. Item 9.01 indicates financial statements and exhibits were included. No specific details on the affected position, individual names, reasons for change, effective dates, or any quantitative impacts are disclosed.

Unknown8-Kneutralmateriality 5/10

03-02-2026

The company filed a Form 8-K on 2026-02-03 under Item 5.02 disclosing an officer change event dated February 03, 2026. No specific details on the affected officer's name, title (e.g., CEO, CFO), nature of change (appointment or departure), reasons, or compensatory arrangements are provided in the filing excerpt. No quantitative financial metrics, performance comparisons, or governance impacts are mentioned.

FB Financial Corp8-Kneutralmateriality 3/10

03-02-2026

FB Financial Corp filed an 8-K on 2026-02-03 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for change, or any quantitative impacts are disclosed. Sector information is not specified.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.8-Kneutralmateriality 3/10

03-02-2026

Pacific Biosciences of California, Inc. filed an 8-K on February 3, 2026 (AccNo: 0001299130-26-000012, Size: 134 KB), disclosing information under Item 5.02 related to departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on the key position affected, individuals involved, reasons for the change, timing, or any quantitative data are explicitly stated in the provided filing summary. Sector is not specified.

Artisan Partners Asset Management Inc.8-Kneutralmateriality 5/10

03-02-2026

Artisan Partners Asset Management Inc. filed an 8-K on February 3, 2026, disclosing results of operations and financial condition under Item 2.02 and an officer change or related event under Item 5.02, with exhibits under Item 9.01. No specific details on the officer position, appointment/resignation, reasons, financial metrics, or performance comparisons are disclosed in the provided filing information. All quantitative data and named entities remain NOT_DISCLOSED.

ATLANTIC INTERNATIONAL CORP.8-Kneutralmateriality 4/10

03-02-2026

ATLANTIC INTERNATIONAL CORP. filed an 8-K on 2026-02-03 disclosing an officer or director change under Item 5.02, which covers departures, elections, appointments, or compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included. No specific details on affected positions, individuals involved, reasons for change, or any quantitative metrics are disclosed.

AZZ INC8-Kneutralmateriality 3/10

03-02-2026

AZZ INC filed an 8-K on 2026-02-03 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on affected positions, individuals, reasons for changes, quantitative data, or impacts are disclosed.

Dine Brands Global, Inc.8-Kneutralmateriality 6/10

03-02-2026

Dine Brands Global, Inc. filed an 8-K on 2026-02-03 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the affected officer, position, appointment or resignation status, reasons, or timing are disclosed. No quantitative metrics, financial data, or performance comparisons are mentioned.

DOMINION ENERGY, INC8-Kneutralmateriality 3/10

03-02-2026

Dominion Energy, Inc. filed an 8-K on February 3, 2026 (AccNo: 0001193125-26-035749), disclosing an officer change under Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. No specific details on the key position affected, individual involved, reason for change, timing, or any quantitative impacts are disclosed. No positive or negative metrics, financial data, or governance implications are mentioned.

Viatris Inc8-Kneutralmateriality 3/10

03-02-2026

Viatris Inc filed an 8-K on February 3, 2026 (AccNo: 0001140361-26-003477), disclosing an officer change under Item 5.02 related to Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. No specific details on the affected position, individual names, appointment or resignation status, reasons for change, or any quantitative data such as compensation amounts are disclosed in the provided filing summary. No positive or negative metrics are mentioned.

DOLLAR GENERAL CORP8-Kneutralmateriality 5/10

03-02-2026

Dollar General Corp filed an 8-K on 2026-02-03 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. Specific details on the affected position, individual involved, appointment or resignation status, reasons, and any impacts are NOT_DISCLOSED.

Accel Entertainment, Inc.8-Kneutralmateriality 3/10

03-02-2026

Accel Entertainment, Inc. filed an 8-K on 2026-02-03 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on positions affected, individuals involved, reasons for change, or quantitative impacts are disclosed.

HP INC8-Kneutralmateriality 6/10

03-02-2026

HP Inc filed an 8-K on February 3, 2026, disclosing matters under Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). Specific details on leadership changes, financial metrics, governance amendments, or any quantitative data are NOT_DISCLOSED. No positive or negative metrics are provided in the filing summary.

RING ENERGY, INC.8-Kneutralmateriality 5/10

03-02-2026

RING ENERGY, INC. filed an 8-K on 2026-02-03 disclosing an officer change or related event under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the affected position, individual names, reasons for change, or any quantitative metrics are disclosed in the provided filing information. The event is categorized as an Officer Change with no further elaboration on positive or negative governance implications.

ANGIODYNAMICS INC8-Kneutralmateriality 3/10

03-02-2026

AngioDynamics Inc filed an 8-K on 2026-02-03 disclosing officer or director changes under Item 5.02, which covers departures, elections, appointments, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on positions affected, names, reasons, or quantitative impacts were provided.

Get daily alerts with 12 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 35 filings

Subscribe now Browse all digests

🇺🇸 More from United States

View all →

March 25, 2026

US Pre-Market SEC Filings Roundup — March 25, 2026

US Pre-Market SEC Filings Roundup

March 24, 2026

US Merger & Acquisition SEC Filings — March 24, 2026

US Merger & Acquisition SEC Filings

March 24, 2026

US Executive Officer Management Changes SEC — March 24, 2026

US Executive Officer Management Changes SEC

March 24, 2026

US Corporate Distress Financial Stress SEC Filings — March 24, 2026

US Corporate Distress Financial Stress SEC Filings

← All United States digests